These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35000806)

  • 1. Real world comparison of spironolactone and eplerenone in patients with heart failure.
    Pardo-Martínez P; Barge-Caballero E; Bouzas-Mosquera A; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Sagastagoitia-Fornie M; Prada-Delgado Ó; Muñiz J; Almenar-Bonet L; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Eur J Intern Med; 2022 Mar; 97():86-94. PubMed ID: 35000806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
    Larsson JE; Denholt CS; Thune JJ; Raja AA; Fosbøl E; Schou M; Køber L; Nielsen OW; Gustafsson F; Kristensen SL
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):546-552. PubMed ID: 37355774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction.
    Serenelli M; Jackson A; Dewan P; Jhund PS; Petrie MC; Rossignol P; Campo G; Pitt B; Zannad F; Ferreira JP; McMurray JJV
    JACC Heart Fail; 2020 Mar; 8(3):188-198. PubMed ID: 31926854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of effects of aldosterone receptor antagonists spironolactone and eplerenone on cardiovascular outcomes and safety in patients with acute decompensated heart failure.
    Yamamoto M; Seo Y; Ishizu T; Nishi I; Hamada-Harimura Y; Machino-Ohtsuka T; Higuchi H; Sai S; Nakatsukasa T; Sugano A; Baba M; Obara K; Aonuma K
    Heart Vessels; 2019 Feb; 34(2):279-289. PubMed ID: 30203391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
    Monzo L; Girerd N; Duarte K; Ferreira JP; McMurray JJV; van Veldhuisen DJ; Swedberg K; Pocock SJ; Pitt B; Zannad F
    Eur J Heart Fail; 2023 Aug; 25(8):1444-1449. PubMed ID: 37370197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
    Elshahat A; Mansour A; Ellabban M; Diaa A; Hassan A; Fawzy A; Saad OA; Abouelmagd M; Eid M; Elaraby A; Elkasaby MH; Abdelaziz A
    BMC Cardiovasc Disord; 2024 Sep; 24(1):489. PubMed ID: 39271992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
    Ferreira JP; Lamiral Z; McMurray JJV; Swedberg K; van Veldhuisen DJ; Vincent J; Rossignol P; Pocock SJ; Pitt B; Zannad F
    Circ Heart Fail; 2021 Jun; 14(6):e008075. PubMed ID: 34129365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
    Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A
    Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
    Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
    Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
    Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study.
    Lund LH; Svennblad B; Melhus H; Hallberg P; Dahlström U; Edner M
    Circ Heart Fail; 2013 Mar; 6(2):174-83. PubMed ID: 23386667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spironolactone and Eplerenone Use at Discharge in Heart Failure Patients With Reduced Ejection Fraction at 3 Large Hospital Systems.
    Jacobs D; Moreno V; Rubio A; Moote R; Lipscomb J; Davis H; Allen S; Oliver A
    Am J Ther; 2023 May; 30(3):e282-e284. PubMed ID: 33852479
    [No Abstract]   [Full Text] [Related]  

  • 20. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.